April 3, 2012

Mayo Clinic-Led Study Finds 2-Drug Combo Slows Advanced Pancreatic Cancer


The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found.  This was evaluated using a measure termed progression-free survival (PFS). According to the results of a multi-center Phase II clinical trial, patients receiving the combination of gemcitabine and TH-302 demonstrated a progression-free survival of 5.6 months compared to 3.6 months in those patients who received gemcitabine alone.

Additional coverage: Science Codex,



HealthCanal   4/3/12

Tags: Cancer, pancreatic cancer, progression-free survival, Research

Please sign in or register to post a reply.
Contact Us · Privacy Policy